Metastasis directed therapy (MDT) is increasingly used in castration-sensitive oligometastatic prostate cancer (OPCa) because it prolongs progression free survival (PFS) and androgen deprivation free survival.
Metastasis directed therapy (MDT) is increasingly used in castration-sensitive oligometastatic prostate cancer (OPCa) because it prolongs progression free survival (PFS) and androgen deprivation free survival.